Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 07, 2015 4:54 PM ET


Company Overview of Caprion Proteomics, Inc.

Company Overview

Caprion Proteomics, Inc. provides proteomics and immune monitoring services to the pharmaceutical and biotechnology industry in North America, Europe, and Asia. Its capabilities include study design, sample preparation, statistical analysis, biological interpretation, and reporting. The company’s expertise also includes the discovery, qualification, and verification of pharmacodynamic/predictive biomarkers and disease markers in various phases of clinical/pre-clinical studies; multiple reaction monitoring assay development for the rapid multiplexed verification and validation of biomarkers; differential expression studies; protein characterization; host cell protein assays for manufacturing ...

201, avenue Président-Kennedy

Suite 3900

Montreal, QC H2X 3Y7


Founded in 2002





Key Executives for Caprion Proteomics, Inc.

Chief Executive Officer, President and Director
Chief Financial Officer and Senior Vice-President
Senior Vice-President of Scientific Operations
Chief Business Officer and Senior Vice-President
Senior Vice-President of Corporate Development and Diagnostics
Compensation as of Fiscal Year 2015.

Caprion Proteomics, Inc. Key Developments

Caprion Proteomics Announces Study Results on Development of Blood-Based Diagnostic for Lung Cancer Yields Publication in Science Translational Medicine

Caprion Proteomics announced the results of a major study conducted by Indi (Integrated Diagnostics) which suggests that quantification of a combination of blood proteins can accurately distinguish between benign lung nodules and early-stage lung cancer. The study, which was published in Science Translational Medicine (STM) and includes several Caprion scientists as co-authors, indicates that when the relative concentrations of this group of proteins (or 'classifier') is combined, the classifier result is correct more than 90% of the time in diagnosing benign lung nodules. This multiple protein classifier uses a highly sensitive analytic technique called multiple reaction monitoring mass spectroscopy (MRM-mass spec). The laboratory-based analytical method, combined with sophisticated bioinformatics and systems-biology approaches allowed the researchers to assess the diagnostic power of 371 potential lung cancer biomarkers in millions of different combinations before settling on the diagnostic classifier (set of biomarkers) that these data indicate is most effective.

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Caprion Proteomics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at